Skip to main content
SpringerLink
Log in

Pharmacokinetics of Zidovudine in Children with Symptomatic HIV Infection

  • Original Research Article
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

The pharmacokinetics of zidovudine in 7 haemophiliac children with symptomatic human immunodeficiency virus disease were assessed after administration of oral dosages of 150 and 180 mg/m2 4 times daily separated by at least 2 weeks. The mean duration of zidovudine treatment was 3 months (range 2 to 5 months). The following mean (± SD) pharmacokinetic parameters were determined with the lower and higher doses, respectively; maximum plasma zidovudine concentration 6.34 ± 3.06 vs 7.09 ± 3.56 µmol/L, terminal half-life 0.84 ± 0.10 vs 0.94 ± 0.25h, and appararent oral clearance 48.8 ± 5.7 vs 54.2 ± 11.3 ml/min/kg. Plasma concentrations of the metabolite 3’-azido-3’-deoxy-5’-β-D-glucopyranosyl thymidine (GZDV) were 2- to 3-fold greater than those of zidovudine, and the terminal portion of the plasma concentration profile of GZDV declined in parallel with that of zidovudine. The pharmacokinetic parameters of zidovudine in these children were very similar to those previously observed in adults. However, there is a suggestion that the apparent oral clearance may be slightly greater in children (present study 49 to 54 ml/min/kg) than in adults (approximately 40 ml/min/kg).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Balis FM, Pizzo PA, Eddy J, Wilfret C, McKinney R, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human ammunodeficiency virus infection. Journal of Pediatrics 114: 880–884, 1989b

    Article  PubMed  CAS  Google Scholar 

  • Balis FM, Pizzo PA, Murphy RF, Eddy J, Jarosinsky PF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Annals of Internal Medicine 110: 279–285, 1989a

    PubMed  CAS  Google Scholar 

  • Barry M, Howe J, Back D, Breckenridge A, Brettle R, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. British Journal of Clinical Pharmacology 36: 82–85, 1993

    Article  PubMed  CAS  Google Scholar 

  • Barry M, Howe JL, Back DJ, Swart AM, Breckenridge AM, et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. British Journal of Clinical Pharmacology 37: 7–12, 1994

    Article  PubMed  CAS  Google Scholar 

  • Blanche S, Caniglia M, Fischer A, Rouzioux C, Burgard M, et al. Zidovudine therapy in children with acquired immunodeficiency syndrome. American Journal of Medicine 85(Suppl 2A): 203–207, 1988

    PubMed  CAS  Google Scholar 

  • Blanche S, Duliege AM, Navarette MS, Tardieu M, Debre M, et al. Low dose zidovudine in children with an HIV-1 infection acquired in the post natal period. Pediatrics 88: 364–370, 1991

    PubMed  CAS  Google Scholar 

  • Boucher ED, Modin JF, Weiler S, Ruff A, Mirochnick M, et al. Phase 1 evaluation of zidovudine administration to infants exposed at birth to the human immunodeficiency virus. Journal of Pediatrics 122: 137–144, 1993

    Article  PubMed  CAS  Google Scholar 

  • Centers for Disease Control. Revision of the CI-surveillance case definition for acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report 36(Suppl. 1): 1–15, 1987

    Google Scholar 

  • Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine: an overview of current data. Clinical Pharmacokinetics 17: 1–9, 1989

    Article  PubMed  CAS  Google Scholar 

  • Dutton GJ. Development aspects of drug conjugation with special reference to glucuronidation. Annual Review of Pharmacology and Toxicology 18: 17–35, 1978

    Article  PubMed  CAS  Google Scholar 

  • Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: a double blind placebo controlled trial. New England Journal of Medicine 317: 185–191, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gallicano K, Sahai J, Ormsby E, Cameron DW, Pakuts A, et al. Pharmacokinetics of zidovudine after the inital single dose and during chronic-dose therapy in HIV-infected patients. British Journal of Clinical Pharmacology 36: 128–131, 1993

    Article  PubMed  CAS  Google Scholar 

  • Gianquinto C, Cozzani S, Plebani A, Ferrazin A, Marchisio P, et al. Pharmacokinetics and long term tolerence of twice daily zidovudine administration in children with mildly symptomatic HIV infection. Journal of Pediatrics, in press, 1994

    Google Scholar 

  • Good SS, Koble CS, Crouch R, Johnson RL, Rideout JL, et al. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metabolism and Disposition 18: 321–326, 1990

    PubMed  CAS  Google Scholar 

  • Graham NM, Zeger SL, Park LP, Vermund SH, Detels R, et al. The effects on survival of early treatment of human immunodeficiency virus infection. New England Journal of Medicine 326: 1037–1042, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. New England Journal of Medicine 36: 427–443, 1991

    Google Scholar 

  • Laskin OL, deMiranda P, Blum MR. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. Journal of Infectious Diseases 159: 745–747, 1989

    Article  PubMed  CAS  Google Scholar 

  • McDougal JD, Martin LS, Cort SP, Mozen M, Heidebrandt CN, et al. Thermal inactivation of the acquired immunodeficiency virus. Journal of Clinical Investigation 77: 875–877, 1985

    Article  Google Scholar 

  • McKinney RE, Maha MA, Connor EM, Feinberg J, Scott GB, et al. A multicentre trial of oral zidovudine in children with advanced human immunodeficiency virus disease. New England Journal of Medicine 224: 1018–1025, 1991

    Article  Google Scholar 

  • McKinney RE, Pizzo PA, Scott GB, Parks WP, Maha MA, et al. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus infected paediatric patients. Journal of Pediatrics 116: 640–647, 1990

    Article  PubMed  Google Scholar 

  • Paediatric Zidovudine Phase 1 Study Group. Safety and tolerence: two year follow up. Paediatric Research 25(Suppl. 186A): 1989

    Google Scholar 

  • Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. New England Journal of Medicine 319: 799–806, 1988

    Article  Google Scholar 

  • Sahai J, Gallicano K, Garber G, Pakuts A, Hawley-Foss N, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 52: 464–470, 1992

    Article  PubMed  CAS  Google Scholar 

  • Singlas E, Pioger JC, Taburet AM, Colaneri S, Fillastre JP. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (GAZT) in healthy subjects and HIV seropositive patients. European Journal of Clinical Pharmacology 36: 639–640, 1989

    Article  PubMed  CAS  Google Scholar 

  • Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. New England Journal of Medicine 322: 941–949, 1990

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, University of Liverpool, New Medical Building, Ashton Street, PO Box 147, Liverpool, L69 3BX, England

    M. Barry, J. L. Howe & D. J. Back

  2. Hospital of Sick Children, London, England

    I. Han

  3. Institute of Child Health, London, England

    D. Gibb

Authors
  1. M. Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. L. Howe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. J. Back
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Gibb
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barry, M., Howe, J.L., Back, D.J. et al. Pharmacokinetics of Zidovudine in Children with Symptomatic HIV Infection. Drug Invest 7, 143–147 (1994). https://doi.org/10.1007/BF03258466

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258466

Keywords

Search

Navigation